Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Organon (DE:7XP)
FRANKFURT:7XP
Organon (7XP) Stock Price & Analysis
1 Followers
7XP Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€9.89 - €20.67
Previous Close€17.39
Volume1.00K
Average Volume (3M)209.00
Market Cap
€4.49B
Enterprise Value€12.02B
Total Cash (Recent Filing)$693.00M
Total Debt (Recent Filing)$8.76B
Price to Earnings (P/E)N/A
Beta0.69
Next Earnings
Aug 07, 2024EPS EstimateN/A
Next Dividend Ex-Date
May 10, 2024Dividend Yield6.02%
Share Statistics
EPS (TTM)N/A
Shares Outstanding255,638,256
10 Day Avg. Volume52
30 Day Avg. Volume209
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-0.92
Price to Sales (P/S)0.71
Price to Cash Flow (P/CF)3.00
P/FCF Ratio2.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.92
Enterprise Value/Gross Profit3.21
Enterprise Value/Ebitda13.75
Forecast
1Y Price Target
€19.33Price Target Upside6.71% Upside
Rating ConsensusHold
Number of Analyst Covering5
Organon News
PremiumCompany Announcements
Organon Q1 2024 Financial Results Presentation Update
PremiumCompany Announcements
Organon & Co. Is Worried About This – Should You Be Worried Too?
PremiumCompany Announcements
Organon Reports Quarterly and Annual Financial ResultsBulls Say, Bears Say
Bulls Say
Dividend PolicyBiosimilars outperformed and free cash flow was stronger than expected, prompting management to express their commitment to the dividend.
Financial PerformanceOGN shares outperformed driven by a combination of factors including delivery of solid 4Q results across all three business segments.
Guidance UpdateUpdated FY24 guidance included an improvement to EBITDA margin expectations due to OPEX discipline.
Bears Say
Portfolio UpdatesThe absence of significant updates to the company's product portfolio in the near term may lead to investor concerns and downward pressure on the stock.
Research And DevelopmentReductions in R&D spending could delay the acquisition of essential assets, potentially affecting the stock as it approaches the Nexplanon loss of exclusivity period.
Revenue EstimatesAnalyst expects lower revenue estimates for Nexplanon and Hadlima, which could negatively impact the stock performance.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
3.82% Other Institutional Investors
96.18% Public Companies and
Individual Investors
7XP FAQ
What was Organon’s price range in the past 12 months?
Organon lowest stock price was €9.89 and its highest was €20.67 in the past 12 months.
What is Organon’s market cap?
Currently, no data Available
When is Organon’s upcoming earnings report date?
Organon’s upcoming earnings report date is Aug 07, 2024 which is in 94 days.
How were Organon’s earnings last quarter?
Organon released its earnings results on May 02, 2024. The company reported €1.139 earnings per share for the quarter, beating the consensus estimate of €0.913 by €0.226.
Is Organon overvalued?
According to Wall Street analysts Organon’s price is currently Undervalued.
Does Organon pay dividends?
Organon pays a Quarterly dividend of €0.26 which represents an annual dividend yield of 6.02%. See more information on Organon dividends here
What is Organon’s EPS estimate?
Organon’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Organon have?
Currently, no data Available
What happened to Organon’s price movement after its last earnings report?
Organon reported an EPS of €1.139 in its last earnings report, beating expectations of €0.913. Following the earnings report the stock price went up 4.17%.
Which hedge fund is a major shareholder of Organon?
Among the largest hedge funds holding Organon’s share is Slate Path Capital LP. It holds Organon’s shares valued at 52M.
---
Organon Stock Smart Score
Company Description
Organon
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
---
7XP Company Deck
---
7XP Earnings Call
Q1 2024
0:00 / 0:00
---
7XP Stock 12 Months Forecast
Average Price Target
€19.33
▲(6.71% Upside)
Technical Analysis
Best Analysts Covering 7XP
1 Year
1 Year Success Rate
6/6 ratings generated profit
1 Year Average Return
+16.63%
assigned a buy rating 4 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +16.63% per trade.
---